poisar

Stock

Dr. Reddy's Laboratories Limited RDY

$12.19+0.58%

Overview

RDY market data

Price History

RDY price chart · 1M
O
12.12
H
12.23
L
12.07
C
12.19
Vol
252,588.00
Source
US equities market feed
Observed
Aug 21, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$12.12
Previous Close
$12.12
Day High
$12.23
Day Low
$12.07
52 Week High
$15.58
52 Week Low
$11.30
7 Day Return
-0.65%
30 Day Return
+7.50%
90 Day Return
-10.89%
1 Year Return
-13.97%
Daily Notional Volume
$3.1M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
31.22
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$50.35
Diluted earnings per share over the trailing twelve months.
Beta
0.18
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
0.7%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
9.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1,101.00 – $1,414.90
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1T · P/B 2.76 · P/S 3.03.

Company News

10 captured
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement TerminationBenzinga · Aug 7, 2026, 3:36 PM
Dr. Reddy's Expands Hospital Portfolio With First-To-Market Sugammadex Injection Launch, Targeting Neuromuscular Blockade Reversal In Surgery PatientsBenzinga · Aug 4, 2026, 6:50 AM
Dr. Reddy’s Laboratories Announces U.S. FDA Completes Inspection at Srikakulam Unit, Issues Form 483Benzinga · Jul 29, 2026, 4:29 PM
Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff ThreatBenzinga · Jul 22, 2026, 6:12 PM
Dr. Reddy's Laboratories shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, President Trump announced a 100% import tariffs on imported generic drugs after a two-year grace period.Benzinga · Jul 22, 2026, 2:33 PM
Dr. Reddy's Executive During Earnings Conference Call Says Company Has Launched Generic Semaglutide Tablets In India; Not Practical To Move To U.S. Immediately Amid Tariff Environment; Working To Resume Semaglutide Supplies At Earliest; Hoping To Get Semaglutide To Market By NovemberBenzinga · Jul 22, 2026, 12:33 PM
Dr Reddy's Laboratories Q1 EPS $0.06 Misses $0.17 Estimate, Sales $853.000M Miss $925.530M EstimateBenzinga · Jul 22, 2026, 11:30 AM
Earnings Scheduled For July 22, 2026Benzinga · Jul 22, 2026, 11:11 AM
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesGlobenewswire Inc · Jul 20, 2026, 4:15 PM
Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial PneumoniaBenzinga · Jun 16, 2026, 12:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock